Venture&Growth
Location
Munich, Germany
Edwin de Graaf
Managing Partner
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Amphista Therapeutics
Amphista Therapeutics is a UK-based biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural...
Vapotherm
US-based MedTech company commercializing oxygen therapy for patients in respiratory distress.
Nalu Medical
Nalu Medical is a US medical device company that develops and commercializes neuromodulation systems for...
